Testing for Lyme disease in the United States follows a two-tiered sequence rather than a single result. The structure explains most of the confusion surrounding negative tests in symptomatic patients.
The tests detect antibodies, not the bacterium
Standard testing looks for the immune system's antibody response to the bacterium rather than for the organism itself, which is present in blood only briefly and in small numbers.
Antibody production takes time. In the first weeks after a bite, the response may not yet be detectable, so a negative result early in infection does not exclude it.
This is why a characteristic expanding rash is treated as sufficient for diagnosis without testing, since serology at that stage is expected to be unreliable. Treatment decisions in that window rest on the rash and exposure history rather than on waiting for a laboratory confirmation that may not arrive.
Two tiers trade sensitivity against specificity
The first test is designed to be sensitive, catching nearly all true cases at the cost of flagging some samples that are not infections.
The second test is more specific, examining the antibody response in detail to confirm that reactivity is directed at the relevant organism rather than a cross-reacting one.
Running them in sequence, with the second performed only on positive or equivocal first results, produces far fewer false positives than either test used alone.
Modified versions of the sequence allow a second immunoassay in place of the older confirmatory format, which keeps the two-step logic while simplifying laboratory workflow.
Antibodies persist after treatment
Antibody levels can remain detectable for months or years after successful treatment, so a positive result cannot distinguish current infection from a past resolved one.
Repeat testing to confirm cure is therefore not informative, and clinical assessment rather than serology determines whether symptoms reflect ongoing infection.
The same persistence explains why people living in high-exposure areas can test positive without recalling an illness, since a past infection leaves the same antibody trace as a treated one.
Geography and exposure change how results are read
Test performance depends on how common the disease is in the population being tested. In areas where infection is rare, a larger share of positive results are false.
Clinicians therefore weigh exposure history, tick habitat, season and symptom pattern alongside the result, and testing without plausible exposure produces more confusion than information. Tick species and regional distribution matter here, because the bacterium is carried by particular ticks concentrated in particular parts of the country.
Where the controversy sits
Persistent symptoms after treated infection are documented and studied, while the interpretation of alternative laboratory panels offered outside standard validation remains contested.
Anyone with a possible exposure, a spreading rash or unexplained persistent symptoms needs an evaluating physician, because the diagnosis rests on the clinical picture rather than a laboratory number alone.